Nanotechnology-Based Drug Delivery to Improve the Therapeutic Benefits of NRF2 Modulators in Cancer Therapy

Creative Commons License

SEZGİN BAYINDIR Z., Losada-Barreiro S., Bravo-Diaz C., Sova M., Kristl J., Saso L.

ANTIOXIDANTS, cilt.10, sa.5, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 10 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.3390/antiox10050685
  • Dergi Adı: ANTIOXIDANTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, Food Science & Technology Abstracts, Directory of Open Access Journals
  • Anahtar Kelimeler: NRF2 modulators, anticancer agents, nanoparticles, drug delivery, drug targeting, SOLID LIPID NANOPARTICLES, SENSITIVE POLYMERIC MICELLES, IN-VITRO EVALUATION, BREAST-CANCER, ANTITUMOR-ACTIVITY, SIGNALING PATHWAY, RECENT PROGRESS, LUNG-CANCER, LIPOSOME ENCAPSULATION, POTENTIAL APPLICATIONS
  • Ankara Üniversitesi Adresli: Evet

Özet

The disadvantages of conventional anticancer drugs, such as their low bioavailability, poor targeting efficacy, and serious side effects, have led to the discovery of new therapeutic agents and potential drug delivery systems. In particular, the introduction of nano-sized drug delivery systems (NDDSs) has opened new horizons for effective cancer treatment. These are considered potential systems that provide deep tissue penetration and specific drug targeting. On the other hand, nuclear factor erythroid 2-related factor 2 (NRF2)-based anticancer treatment approaches have attracted tremendous attention and produced encouraging results. However, the lack of effective formulation strategies is one of the factors that hinder the clinical application of NRF2 modulators. In this review, we initially focus on the critical role of NRF2 in cancer cells and NRF2-based anticancer treatment. Subsequently, we review the preparation and characterization of NDDSs encapsulating NRF2 modulators and discuss their potential for cancer therapy.